Episode Details
Back to EpisodesCOVID-19 clinical update #112 with Dr. Daniel Griffin
Episode 895
Published 3 years, 8 months ago
Description
In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Seroprevalence of Infection-Induced Antibodies (CDC)
- Authorization for Vaccine in Young Children Filed (Moderna)
- Public Health Impact of Vaccines in US (BMJ)
- FDA authorizes first approved treatment for children (FDA)
- Phase 2 Data for Sabizabulin (Veru Pharma)
- Clinical Characteristics of Post Infection Inflammation (The Lancet)
- Fact Sheet for Providers on Evusheld (FDA)
- Fact Sheet for Providers on Paxlovid (FDA)
- Provider Referral for EvuSheld (Northwell Health)
- Contribute to ASTMH fundraiser at PWB
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 895
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv